Browsing by Author "Murenzi, Gad"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Hepatitis B and C Prevention, Screening, and Diagnostic Services at HIV Treatment Sites: International Epidemiology Databases to Evaluate AIDS.
    (2026-Sep-01) Kuniholm, Mark H.; Murenzi, Gad; Samala, Niharika; Yunihastuti, Evy; Wandeler, Gilles ; Kim, Nina H.; Plaisy, Marie K.; Perazzo, Hugo; Twizere, Christella; Odhiambo, Francesca; Bopage, Rohan ; Muula, Guy; Lo Re, Vincent; Minga, Albert; López-Iñiguez, Alvaro; Nsonde, Dominique M.; Kasozi, Charles; Wati, Dewi K.; Fox, Matthew P.; Kirk, Gregory D.; Messou, Eugene; Cesar, Carina; Ebasone, Peter V.; Byakwaga, Helen; Ross, Jeremy; Chimbetete, Cleophas ; Yendewa, George A.; Jaquet, Antoine; Succi, Regina C. M.; Maruri, Fernanda; Brazier, Ellen
    BACKGROUND: Prevention, screening, and diagnostic services for hepatitis B virus (HBV) and hepatitis C virus (HCV) can prevent morbidity and mortality in people receiving HIV care. However, there is limited information about the availability of HBV and HCV services at HIV clinics globally. METHODS: The International epidemiology Databases to Evaluate AIDS (IeDEA) conducted surveys of service delivery and practices at participating HIV treatment centers from 7 regions. We used 2023 survey data to measure availability of HBV vaccination, HBV and HCV screening, HBV surface antigen (HBsAg), HBV DNA, HCV antibody, and HCV RNA testing. Multivariable logistic regression models were used to test associations of site characteristics with HBV and HCV services. RESULTS: HBV vaccination was available on-site at 67.7% of 204 HIV treatment sites. Screening for HBV and HCV at HIV care enrollment was reported by 72.1% and 50% of sites, respectively. HBsAg, HBV DNA, HCV antibody, and HCV RNA testing were available on-site at 77%, 47.6%, 61.8%, and 44.6% of sites, respectively. Sites serving predominately rural (vs. urban) populations were less likely to report on-site availability of HBV DNA [odds ratio (OR):0.07; 95% confidence interval: 0.01 to 0.68; P = 0.02], HCV antibody (OR = 0.18; 95% CI: 0.04 to 0.92; P = 0.04), and HCV RNA (OR = 0.10; 95% CI: 0.01 to 0.90; P = 0.04) testing. CONCLUSION: Life-saving services such as HBV vaccination, HBsAg, and HCV antibody testing were available on-site at most HIV treatment sites participating in the IeDEA network. Lower availability at rural sites suggests that expansion of services is important to eliminate HBV and HCV as public health problems in people receiving HIV care.
  • Thumbnail Image
    Item
    Under the Influence: Alcohol, Substance Use and Treatment Adherence in Youth Living with HIV in the Global Adolescent and Young Adult Network of IeDEA (AYANI) Cohort.
    (2026-Apr-21) van Dongen, Nicola; Technau, Karl-Günter ; Jaguga, Florence; Murenzi, Gad; Machado, Daisy M.; Amorissani-Folquet, Madeleine; Ditango, Rossana; Mureithi, Fiona; McCoy, Brittany; Brazier, Ellen; Luque, Marco T.; Jesson, Julie; Phuthanakit, Thanyawee; Maxwell, Nicola; Vreeman, Rachel; Elul, Batya; Pinto, Jorge A.; Oka, Gladis; Sudjaritruk, Tavitiya; Kanguya, Tukiya; Enane, Leslie; Ryumugabe, Diane; Hilaire, Genevieve; Leroy, Valériane; Sohn, Annette H.; Brehm, Aaron; Anderson, Kim